VT6 주식 개요 생명공학 회사인 보이저 테라퓨틱스는 유전자 치료와 신경학 질환 치료에 주력하고 있습니다. 자세한 내용
{"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
Voyager Therapeutics, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Voyager Therapeutics 과거 주가 현재 주가 US$5.09 52주 최고치 US$9.90 52주 최저치 US$4.80 베타 0.91 1개월 변경 -6.87% 3개월 변경 사항 -24.44% 1년 변경 사항 -28.38% 3년 변화 64.14% 5년 변화 -56.54% IPO 이후 변화 -72.32%
최근 뉴스 및 업데이트
Voyager Therapeutics, Inc. Provides Update on Sod1 Als Gene Therapy Program Feb 11
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023) Nov 13
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Investor sentiment deteriorates as stock falls 22% Oct 24
Investor sentiment improves as stock rises 23% Oct 08 더 많은 업데이트 보기
Voyager Therapeutics, Inc. Provides Update on Sod1 Als Gene Therapy Program Feb 11
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023) Nov 13
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Investor sentiment deteriorates as stock falls 22% Oct 24
Investor sentiment improves as stock rises 23% Oct 08
Investor sentiment deteriorates as stock falls 23% Aug 14
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023) Aug 07
Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index Jul 03
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024 Jun 15
Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease May 18
First quarter 2024 earnings released: US$0.20 loss per share (vs US$3.05 profit in 1Q 2023) May 14
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting May 09
Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
Investor sentiment improves as stock rises 16% May 04
Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
President recently sold €111k worth of stock Apr 05
Investor sentiment improves as stock rises 17% Apr 02
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 15
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 13
Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022) Feb 29
Investor sentiment improves as stock rises 27% Feb 29
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment Feb 28
President recently sold €90k worth of stock Feb 27
Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research Feb 20
New major risk - Shareholder dilution Jan 09
Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Jan 06 Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.
Investor sentiment improves as stock rises 26% Jan 02
Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program Dec 06
Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022) Nov 07
Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Chief Financial Officer recently sold €91k worth of stock Oct 06
Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022) Aug 04
Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Investor sentiment deteriorates as stock falls 16% Jul 13
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer Jul 11
Investor sentiment improves as stock rises 16% Jun 12
Investor sentiment improves as stock rises 19% May 18
Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee May 10
First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022) May 10
President recently sold €54k worth of stock Apr 09
Chief Operating Officer recently sold €120k worth of stock Mar 22
Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021) Mar 09
Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023 Dec 15
Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021) Nov 09
Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families Oct 12 Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022
Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021) Aug 06 Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models Aug 04
Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Aug 03
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors Jul 29
Voyager Therapeutics, Inc. Announces Executive Changes Jun 09
Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction May 20
Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting May 18
First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021) May 06
Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022 Apr 22
Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board Apr 21
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Voyager Therapeutics, Inc. Announces Executive Appointments Feb 04
Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020) Nov 03
Investor sentiment deteriorated over the past week Oct 27
Investor sentiment improved over the past week Oct 07
Investor sentiment improved over the past week Sep 06
Investor sentiment deteriorated over the past week Aug 17
Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020) Aug 10 Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates May 12
First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.66 loss in 1Q 2020) May 11
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease Apr 27
Investor sentiment improved over the past week Apr 26
Full year 2020 earnings released: EPS US$0.99 (vs US$1.21 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Feb 26
New 90-day low: €5.30 Feb 20
Voyager Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Voyager Therapeutics, Inc Feb 17
Neurocrine Biosciences, Inc. Enters into Partial Termination of the Collaboration and License Agreement with Voyager Therapeutics, Inc Feb 03
Pomerantz Law Firm Announces the Filing of Class Action Against Voyager Therapeutics, Inc Jan 24
Wendy Dixon Decides to Resign from the Board and All Committees of Voyager Therapeutics, Inc Jan 16
Investor sentiment improved over the past week Jan 09
New 90-day low: €6.00 Dec 30
Investor sentiment deteriorated over the past week Dec 29
New 90-day low: €6.45 Dec 11
Market pulls back on stock over the past week Nov 16
Third quarter 2020 earnings released: EPS US$2.30 Nov 11 주주 수익률 VT6 DE Biotechs DE 마켓 7D 1.1% 1.2% 2.3% 1Y -28.4% -5.6% 16.7%
전체 주주 수익률 보기
수익률 대 산업: VT6 지난 1년 동안 -5.6 %를 반환한 German Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: VT6 지난 1년 동안 16.7 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is VT6's price volatile compared to industry and market? VT6 volatility VT6 Average Weekly Movement 10.0% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
안정적인 주가: VT6 의 주가는 지난 3개월 동안 German 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: VT6 의 주간 변동성 ( 10% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 생명공학 회사인 보이저 테라퓨틱스는 유전자 치료 및 신경학 질환 치료에 주력하고 있습니다. 이 회사의 주요 임상 후보 물질은 알츠하이머병 치료를 위한 항타우 항체 프로그램인 VY-TAU01입니다. 근위축성 측삭 경화증 치료를 위해 전임상 시험 중인 슈퍼옥사이드 디스뮤타제 1 침묵 유전자 치료제, 알츠하이머병 치료를 위해 전임상 시험 중인 타우 침묵 유전자 치료제, 알츠하이머병 치료를 위한 항 아밀로이드 표적 유전자 치료제인 벡터화 항 아밀로이드 항체 등이 제품 파이프라인에 포함되어 있으며 전임상 시험을 진행 중입니다.
자세히 보기 Voyager Therapeutics, Inc. 기본 사항 요약 Voyager Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? VT6 기본 통계 시가총액 €280.32m 수익(TTM ) €24.96m 수익(TTM ) €157.99m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) VT6 손익 계산서(TTM ) 수익 US$163.78m 수익 비용 US$117.54m 총 이익 US$46.24m 기타 비용 US$20.36m 수익 US$25.88m
주당 순이익(EPS) 0.47 총 마진 28.23% 순이익 마진 15.80% 부채/자본 비율 0%
VT6 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/11 16:11 장 마감 주가 2025/02/11 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 Voyager Therapeutics, Inc. 26 애널리스트 중 12 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Brian Skorney Baird Jack Allen Baird Aydin Huseynov Benchmark Company
23 더 많은 분석가 보기 
